Renaissance Capital logo

Lux Health Tech Acquisition Priced, Nasdaq: LUXAU

Blank check company formed by Lux Capital targeting a healthtech business.

Industry: SPAC

Latest Trade: $12.30 0.00 (0.0%)

First Day Return: +0.1%

Return from IPO: +23.0%

Industry: SPAC

We are a newly incorporated blank check company. We intend to capitalize on the ability of our management team to identify, acquire and operate a business at the intersection of the healthcare and technology industries. Our management team and board of directors will be led by Peter Hébert, our Chairman. Josh DeFonzo will serve as our Chief Executive Officer, and a member of our board of directors. Segolene Scarborough will serve as our Chief Financial Officer and Treasurer. We expect Dr. Bijan Salehizadeh, Senator Joseph Robert "Bob" Kerrey and Dr. Fred Moll to join our board of directors at the closing of this offering. Mr. Peter Hébert is a co-founder and managing partner of Lux and oversees Lux’s investments at the intersection of technology and medical devices, including Auris Health, which was acquired by Johnson & Johnson, and Avail Medsystems. Mr. Josh DeFonzo is a former President at Johnson & Johnson (Robotics & Digital Solutions), the former Chief Operating Officer of Auris Health, and a former Chief Commercial Officer of CareDx (Nasdaq: CDNA).
more less
IPO News for Lux Health Tech Acquisition
more
IPO Data
IPO File Date 10/09/2020
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 30.0
Deal Size ($mm) $300
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/26/2020
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 30.0
Deal Size ($mm) $300
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2020
Employees 3
Website luxcapital.com